Company Overview
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. Position Overview The Vice President/Executive Director, Medical Affairs will lead three key functions-Medical Science Liaisons (MSLs), Patient Advocacy, and Medical Information. This role is central to building Immunome's external presence, gathering insights to shape strategy, and driving stakeholder engagement across healthcare and patient communities. This is a highly dynamic role: the ideal candidate will be able to roll up their sleeves and do the groundwork while leading the development of evolving functions. This is a hybrid role based in Bothell, WA and requires three days a week in-office on a weekly basis. Responsibilities National MSL Leadership:
Patient Advocacy Leadership:
Medical Information Leadership:
Cross-functional Expectations:
Qualifications
Knowledge and Skills
WA Pay Range for Vice President: $364,764 - $428,500
...CREx is transforming the $4 trillion commercial real estate industry with value-driven technology advisory and solutions. As a fast-... ...The Opportunity We are seeking an experienced Senior Consultant to support client engagements, contribute to strategic growth...